Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
symptoms during the preceding 0.5-mg treatment period were not systematically collected in this study and were, therefore, not available for formal comparison
Orforglipron, an oral GLP-1 candidate, recently delivered compelling Phase 3 results as the first oral, non-peptide GLP-1 agonist to match the efficacy of injectable therapiespotentially revolutionizing the patient experience in weight-loss treatment
Researchers noted that weight loss success, income level, medication costs and adverse effects were associated with decisions to continue or stop the medication
This stepwise escalation is designed to improve tolerability, particularly in relation to gastrointestinal side effects
